Tempo Therapeutics Awarded $2.25 Million NIH SBIR Grant to Advance MAP™ Technology for Complex Wound Healing
Tempo Therapeutics Closes Oversubscribed $14.5 Million Financing to Advance MAP(TM) Regenerative Technology
Tempo Therapeutics Announces First Patient Dosed in Clinical Trial of TT101 For Tissue Repair in Skin Cancer Surgery
Tempo Therapeutics Secures Series A Financing to Advance Cutting-Edge Tissue Scaffold Products into Clinical Trials
